Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.60 |
| ▸ | TNKS | O95271 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | TOP1 | P11387 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15131095 | 0.79 | KMT2A (0.56) | MEN1KMT2ATNKSKDM4EALDH1A1 | |
| SCHEMBL21037223 | 0.79 | KMT2A (0.56) | MEN1KMT2ATNKSKDM4EALDH1A1 | |
| SCHEMBL4489136 | 0.77 | KMT2A (0.57) | MEN1KMT2ATNKSKDM4EALDH1A1 | |
| SCHEMBL14209236 | 0.76 | KMT2A (0.56) | MEN1KMT2ATNKSKDM4EALDH1A1 | |
| SCHEMBL11326239 | 0.75 | KMT2A (0.53) | MEN1KMT2ATNKSKDM4EALDH1A1 | |
| SCHEMBL4497665 | 0.74 | MEN1 (0.55) | MEN1KMT2ATNKSKDM4EALDH1A1 | |
| SCHEMBL14209188 | 0.73 | MEN1 (0.47) | MEN1KMT2AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL4497379 | 0.73 | MEN1 (0.54) | MEN1KMT2ATNKSKDM4EALDH1A1 | |
| SCHEMBL4492144 | 0.73 | KMT2A (0.54) | MEN1KMT2ATNKSKDM4EALDH1A1 | |
| SCHEMBL4487724 | 0.73 | KMT2A (0.54) | MEN1KMT2ATNKSKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289813-A2 | INTERMEDIATES TO OBTAIN SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | Global Blood Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3738434-A1 | INTERMEDIATES TO OBTAIN SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | Global Blood Therapeutics, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3141542-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | Global Blood Therapeutics, Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20160206614-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. | 2016-07-21 | — | — | US | disclosed |
| US-20150344472-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. | 2015-12-03 | — | — | US | disclosed |
| US-9018210-B2 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20130190315-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2013102142-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344472-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | MEN1 4829/4885KMT2A 1436/4885TNKS 2509/4885 |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | HAVCR2, GLS2, EIF2AK2 | MEN1 4880/4885KMT2A 4081/4885TNKS 3417/4885 |
| US-20160206614-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | MEN1 4829/4885KMT2A 1436/4885TNKS 2509/4885 |
| US-20130190315-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | MEN1 4829/4885KMT2A 1436/4885TNKS 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.